ES2075433T3 - Compuestos marcados con 19f como agentes de formacion de imagenes y de espectroscopia por rmn. - Google Patents

Compuestos marcados con 19f como agentes de formacion de imagenes y de espectroscopia por rmn.

Info

Publication number
ES2075433T3
ES2075433T3 ES91905554T ES91905554T ES2075433T3 ES 2075433 T3 ES2075433 T3 ES 2075433T3 ES 91905554 T ES91905554 T ES 91905554T ES 91905554 T ES91905554 T ES 91905554T ES 2075433 T3 ES2075433 T3 ES 2075433T3
Authority
ES
Spain
Prior art keywords
agents
image formation
compounds marked
mri spectroscopy
molecula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91905554T
Other languages
English (en)
Inventor
Peter P Antich
Padmakar V Kulkarni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
The University of Texas System
The University of Texas at Austin
Original Assignee
The University of Texas System
The University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The University of Texas System, The University of Texas at Austin filed Critical The University of Texas System
Application granted granted Critical
Publication of ES2075433T3 publication Critical patent/ES2075433T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/12—Macromolecular compounds
    • A61K49/126—Linear polymers, e.g. dextran, inulin, PEG
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/146—Peptides, e.g. proteins the peptide being a polyamino acid, e.g. poly-lysine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/806—Electrical property or magnetic property
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/24—Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Radiology & Medical Imaging (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)

Abstract

SE PRESENTAN COMPUESTOS ETIQUETADOS COMO 19F QUE SON UTILES EN METODOS DE FORMACION DE IMAGENES NMR Y EN ESPECTROSCOPIA. LOS COMPUESTOS COMPRENDEN UNA MOLECULA SENSORA QUE CONTIENE 19F, Y UN POLIMERO O SUBSTRATO DE TRANSPORTE, Y PUEDEN OPCIONALMENTE COMPRENDER TAMBIEN UNA MOLECULA SEPARADORA PARA SEPARAR LA MOLECULA SENSORA Y EL POLIMERO DE TRANSPORTE.
ES91905554T 1990-02-21 1991-02-21 Compuestos marcados con 19f como agentes de formacion de imagenes y de espectroscopia por rmn. Expired - Lifetime ES2075433T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/482,879 US5236694A (en) 1990-02-21 1990-02-21 19f labelled dextrans and antibodies as nmr imaging and spectroscopy agents

Publications (1)

Publication Number Publication Date
ES2075433T3 true ES2075433T3 (es) 1995-10-01

Family

ID=23917811

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91905554T Expired - Lifetime ES2075433T3 (es) 1990-02-21 1991-02-21 Compuestos marcados con 19f como agentes de formacion de imagenes y de espectroscopia por rmn.

Country Status (9)

Country Link
US (3) US5236694A (es)
EP (1) EP0517788B1 (es)
JP (1) JPH05506432A (es)
AT (1) ATE125712T1 (es)
AU (1) AU641233B2 (es)
CA (1) CA2075953A1 (es)
DE (1) DE69111798T2 (es)
ES (1) ES2075433T3 (es)
WO (1) WO1991012824A2 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5236694A (en) * 1990-02-21 1993-08-17 The Board Of Regents, The University Of Texas System 19f labelled dextrans and antibodies as nmr imaging and spectroscopy agents
US5368840A (en) * 1990-04-10 1994-11-29 Imarx Pharmaceutical Corp. Natural polymers as contrast media for magnetic resonance imaging
US5370901A (en) * 1991-02-15 1994-12-06 Bracco International B.V. Compositions for increasing the image contrast in diagnostic investigations of the digestive tract of patients
GB9216843D0 (en) * 1992-08-07 1992-09-23 Cancer Res Inst Contrast agents for medical imaging
US5468467A (en) * 1993-04-23 1995-11-21 Bracco International B.V. Methods for the in vivo measurement of the concentration of non-imaging nmr-detectable xenobiotic compounds
DE4318369C1 (de) * 1993-05-28 1995-02-09 Schering Ag Verwendung von makrocyclischen Metallkomplexen als Temperatursonden
GB9325330D0 (en) * 1993-12-10 1994-02-16 Univ Toronto Fluorocyclodextrin drug delivery system
EP0831935A4 (en) * 1995-06-07 2001-08-29 Mallinckrodt Medical Inc GASEOUS ULTRASONIC CONTRAST AGENTS AND RELATED METHODS
US5807978A (en) * 1995-06-07 1998-09-15 Kokolus; William J. Immunogenic peptides of prostate specific antigen
US5678548A (en) * 1995-07-20 1997-10-21 The United States Of America As Represented By The Department Of Health And Human Services System and method for performing in vivo imaging and oxymetry and FT microscopy by pulsed radiofrequency electron paramagnetic resonance
US5753207A (en) * 1995-08-21 1998-05-19 Beth Israel Deaconess Medical Center, Inc. Use of paramagnetic compounds to measure temperature and pH in vivo
US5828216A (en) * 1996-08-19 1998-10-27 The United States Of America As Represented By The Department Of Health And Human Services Gated RF preamplifier for use in pulsed radiofrequency electron paramagnetic resonance and MRI
AT409929B (de) * 1997-03-07 2002-12-27 Tritthart Helmut A Dr Polymere-infusionslösung zur anwendung bei der diagnose von tumoren, gegebenenfalls zu deren behandlung
US6419174B1 (en) * 2000-08-18 2002-07-16 J. M. Huber Corporation Abrasive compositions and methods for making same
US6574497B1 (en) 2000-12-22 2003-06-03 Advanced Cardiovascular Systems, Inc. MRI medical device markers utilizing fluorine-19
NO20015802D0 (no) * 2001-11-28 2001-11-28 Amersham Health As Diagnostisk metode
WO2003086563A2 (en) * 2002-04-11 2003-10-23 Carbomer, Inc. Diabetes imaging probes
WO2003087165A2 (en) * 2002-04-11 2003-10-23 Carbomer, Inc. Biocompatible materials and probes
US7090829B2 (en) * 2002-04-11 2006-08-15 Carbomer, Inc. Imaging probes
WO2004078990A1 (en) * 2003-02-28 2004-09-16 Carbomer, Inc. Halogenated emulsans
AU2005209169B2 (en) 2004-01-16 2010-12-16 Carnegie Mellon University Cellular labeling for nuclear magnetic resonance techniques
AU2005310986A1 (en) * 2004-11-12 2006-06-08 Bellus Health (International) Limited Methods and fluorinated compositions for treating amyloid-related diseases
DE102005005704B4 (de) 2005-02-03 2010-08-12 Leibniz-Institut Für Festkörper- Und Werkstoffforschung Dresden E.V. Verwendung von Partikeln für die Ermittlung der lokalen Temperatur in organischen und nichtorganischen Körpern
WO2007120911A2 (en) * 2006-04-14 2007-10-25 Carnegie Mellon University Cellular labeling and quantification for nuclear magnetic resonance techniques
EP2012832A2 (en) * 2006-04-14 2009-01-14 Celsense, Inc. Methods for assessing cell labeling
GB0711662D0 (en) * 2007-06-15 2007-07-25 Cancercure As Magnetic resonance guided cancer treatment system
CA2693678C (en) * 2007-07-10 2017-02-14 Carnegie Mellon University Compositions and methods for producing cellular labels for nuclear magnetic resonance techniques
US8093060B2 (en) * 2008-02-28 2012-01-10 Canon Kabushiki Kaisha Multisite phosphorylated peptide (protein) recognizing compound and detection method, imaging method, alzheimer's disease diagnosing method and reagent kit using the same
WO2009134435A2 (en) * 2008-05-02 2009-11-05 Celsense Inc. Compositions and methods for producing emulsions for nuclear magnetic resonance techniques and other applications
CN102497888B (zh) 2009-07-31 2014-10-29 皇家飞利浦电子股份有限公司 用于成像的全氟化合物
WO2012076191A1 (en) * 2010-12-10 2012-06-14 Merck Patent Gmbh Aptamer labeled with f-19 nucleus for targeted molecular imaging by mri
WO2012142670A1 (en) * 2011-04-20 2012-10-26 The University Of Queensland Nuclear magnetic resonance agent
JP6234064B2 (ja) * 2012-05-23 2017-11-22 キヤノン株式会社 重合体、前記重合体を用いた核磁気共鳴分析用または磁気共鳴イメージング用の造影剤、化合物、前記重合体を用いた核磁気共鳴分析方法および磁気共鳴イメージング方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4631190A (en) * 1981-06-26 1986-12-23 Shen Wei C Acidity-sensitive spacer molecule to control the release of pharmaceuticals from molecular carriers
US4741900A (en) * 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US4640833A (en) * 1983-02-28 1987-02-03 Adamantech, Inc. Use of perfluorobromoalkyl ethers as X-ray contrast agents
US4586511A (en) * 1983-03-04 1986-05-06 Children's Hospital Medical Center Methods and compositions for detecting and imaging a gas in an animal by nuclear magnetic resonance
US4558279A (en) * 1983-03-07 1985-12-10 University Of Cincinnati Methods for detecting and imaging a temperature of an object by nuclear magnetic resonance
US4612185A (en) * 1984-10-15 1986-09-16 Mallinckrodt, Inc. Methods and compositions for enhancing magnetic resonance imaging
SE465907B (sv) * 1984-11-01 1991-11-18 Nyegaard & Co As Diagnosticeringsmedel innehaallande en paramagnetisk metall
US4639364A (en) * 1984-11-14 1987-01-27 Mallinckrodt, Inc. Methods and compositions for enhancing magnetic resonance imaging
US4865836A (en) * 1986-01-14 1989-09-12 Fluoromed Pharmaceutical, Inc. Brominated perfluorocarbon emulsions for internal animal use for contrast enhancement and oxygen transport
US5080885A (en) * 1986-01-14 1992-01-14 Alliance Pharmaceutical Corp. Brominated perfluorocarbon emulsions for internal animal use for contrast enhancement and oxygen transport
US5141739A (en) * 1986-07-03 1992-08-25 Advanced Magnetics, Inc. Delivery of x-ray contrast agents using receptor mediated endocytosis
US4838274A (en) * 1987-09-18 1989-06-13 Air Products And Chemicals, Inc. Perfluoro-crown ethers in fluorine magnetic resonance imaging
US4914210A (en) * 1987-10-02 1990-04-03 Cetus Corporation Oligonucleotide functionalizing reagents
WO1989003693A1 (en) * 1987-10-27 1989-05-05 Fluoromed Pharmaceutical, Inc. Method of using fluorocarbons in nuclear magnetic resonance imaging
GB8801646D0 (en) * 1988-01-26 1988-02-24 Nycomed As Chemical compounds
DE3834704A1 (de) * 1988-10-07 1990-06-07 Schering Ag Fluorsubstituierte benzolderivate
US5116599A (en) * 1989-07-31 1992-05-26 Johns Hopkins Univ. Perfluoro-t-butyl-containing compounds for use in fluorine-19 nmr and/or mri
US5236694A (en) * 1990-02-21 1993-08-17 The Board Of Regents, The University Of Texas System 19f labelled dextrans and antibodies as nmr imaging and spectroscopy agents
US5196348A (en) * 1990-06-11 1993-03-23 Air Products And Chemicals, Inc. Perfluoro-crown ethers in fluorine magnetic resonance spectroscopy of biopsied tissue
US5068098A (en) * 1990-06-11 1991-11-26 Air Products And Chemicals, Inc. Perfluoro-crown ethers in fluorine magnetic resonance spectroscopy

Also Published As

Publication number Publication date
EP0517788B1 (en) 1995-08-02
EP0517788A1 (en) 1992-12-16
DE69111798D1 (de) 1995-09-07
WO1991012824A2 (en) 1991-09-05
US5397562A (en) 1995-03-14
US5422094A (en) 1995-06-06
CA2075953A1 (en) 1991-08-22
US5236694A (en) 1993-08-17
ATE125712T1 (de) 1995-08-15
WO1991012824A3 (en) 1992-02-20
AU7453991A (en) 1991-09-18
JPH05506432A (ja) 1993-09-22
DE69111798T2 (de) 1995-11-30
AU641233B2 (en) 1993-09-16

Similar Documents

Publication Publication Date Title
Graham uvby photometry of white-dwarf stars.
Birtalan et al. Investigating rhodamine B‐labeled peptoids: Scopes and limitations of its applications
ES2161775T3 (es) Procedimiento para teñir fibras que contienen queratina.
ES2059491T3 (es) Derivados de indol con anillos condensados.
ES2146256T3 (es) Agentes de contraste que contienen perfluoro-1h,1h-neopentilo y metodo para usar el mismo.
WO1991012824A3 (en) 19f labelled compounds as nmr imaging and spectroscopy agents
ES2107518T3 (es) Polimeros estabilizados con heteroatomos en la cadena principal.
DE59010061D1 (de) Verfahren zur Herstellung von 2-(2',4'-Dihydroxyphenyl)-4,6-diaryl-s-triazinen
ES2069914T3 (es) Agentes marcadores que comprenden conjugados de acidos boronicos.
ES2068202T3 (es) Composicion liquida suavizante para prendas de ropa.
ES2104881T3 (es) Procedimiento para teñir papel con colorantes diazoicos.
ES8506501A1 (es) Dispositivo de cierre de molde en maquinas manipuladoras de material sintetico
ES2165395T3 (es) Oxazolinas y tiazolinas artropodicidas.
FI844129A0 (fi) Kompositioner baserade pao eldfast polyamid.
ES2043725T3 (es) Aminofenil-carbamatos substituidos.
ES2182851T3 (es) Compuestos de naftoxazina fotocromica.
AR008781A1 (es) Compuestos de furano nitrona
ES2012524A6 (es) Procedimiento para la produccion de colorantes complejos de cromo 1:2.
MX9306035A (es) Nuevas bis-naftalimidas sustituidas en forma asimetrica.
IT8620297A1 (it) Composti stabilizzanti e procedimento per la loro preparazione
NO910957D0 (no) Fluorbenzensulfonamider, fremgangsmaate for fremstilling derav, samt preparat som inneholder slike forbindelser.
ES2079464T3 (es) Derivados dipeptidicos de muramilo.
ES2038740T3 (es) Procedimiento de obtencion de compuesos guanidicos que comprenden un ion tetrafenilborato sustituido.
BR9206084A (pt) Pigmento e processo para produção de pigmentos
BR9002009A (pt) Formulacao de aclarador,estavel a armazenagem,processo para sua preparacao e emprego

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 517788

Country of ref document: ES